Palvella Therapeutics, Inc. (PVLA) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $114.25: Quality below floor (1.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10 and A.R:R 6.2:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 17%; Below-average business quality.
Palvella Therapeutics is a clinical-stage biopharma using its QTORIN platform to develop topical therapies for rare skin diseases and vascular malformations. Lead asset QTORIN rapamycin met its primary endpoint in the Phase 3 SELVA trial for microcystic lymphatic malformations... Read more
Sell if holding. Engine safety override at $114.25: Quality below floor (1.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10 and A.R:R 6.2:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 17%; Below-average business quality. Chart setup: RSI 47 mid-range, Bollinger mid-band. Score 5.1/10, moderate confidence.
Passes 7/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, news events none recent, earnings proximity 59d clear, semi cycle peak clear, materials cycle peak clear). Suitability: aggressive.
Recent developments
updated 2026-06-15Recent Developments — Palvella Therapeutics, Inc.
Latest news
- NEWS Palvella Therapeutics Completes Pre-NDA Meeting With FDA For QTORIN 3.9% Rapamycin Anhydrous Gel In Microcystic Lymphati — benzinga Jun 3, 2026 positive
- NEWS Palvella Therapeutics Receives U.S. Patent For Its Licensed QTORIN Pitavastatin Program For Porokeratosis — benzinga May 27, 2026 positive
- NEWS Stephens & Co. Reiterates Overweight on Palvella Therapeutics, Maintains $220 Price Target — benzinga May 21, 2026 positive
- NEWS Palvella Therapeutics Presents New Clinical Data From Phase 3 SELVA And Phase 2 TOIVA Studies At ISSVA World Congress 20 — benzinga May 20, 2026 positive
- NEWS Palvella Therapeutics Presents New Data From Phase 2 TOIVA Trial Of QTORIN Rapamycin In Patients With Cutaneous Venous M — benzinga May 15, 2026 positive
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelineQTORIN rapamycin10-K Item 1A: 'Our future success is substantially dependent on the successful clinical development, regulatory approval and commercialization of QTORIN rapamycin, which is in later stages of development than our other product candidates.'
Material Events(8-K, last 90d)
- 2026-04-13Item 5.02LOWBoard increased from 6 to 7 members; John Doux, M.D. appointed as Class III director effective April 13, 2026 (term expiring at 2026 Annual Meeting). Routine board expansion; no officer departure.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
5 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Volatile — 6.1% daily ATR makes tight stops impractical. Position-size conservatively.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $114.25: Quality below floor (1.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10 and A.R:R 6.2:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 17%; Below-average business quality. Chart setup: RSI 47 mid-range, Bollinger mid-band. Prior stop was $106.76. Score 5.1/10, moderate confidence.
Take-profit target: $206.64 (+80.0% upside). Prior stop was $106.76. Stop-loss: $106.76.
Concentration risk — Pipeline: QTORIN rapamycin; Quality below floor (1.2 < 4.0).
Palvella Therapeutics, Inc. trades at a P/E of N/A (forward -16.0). TrendMatrix value score: 9.0/10. Verdict: Sell.
23 analysts cover PVLA with a consensus score of 4.3/5. Average price target: $230.
What does Palvella Therapeutics, Inc. do?Palvella Therapeutics is a clinical-stage biopharma using its QTORIN platform to develop topical therapies for rare...
Palvella Therapeutics is a clinical-stage biopharma using its QTORIN platform to develop topical therapies for rare skin diseases and vascular malformations. Lead asset QTORIN rapamycin met its primary endpoint in the Phase 3 SELVA trial for microcystic lymphatic malformations (February 2026); NDA submission is planned for H2 2026. QTORIN pitavastatin targets DSAP in IND-enabling development.